Anti-IAV HA Recombinant Antibody (Gedivumab) (CAT#: TAB-027ML)

Figure 1 Anti-IAV HA Recombinant Antibody (TAB-027ML) in SDS-PAGE

SDS-PAGE analysis of TAB-027ML in non-reduced (Lane 1, 1.5 μg) and β-mercaptoethanol-reduced (Lane 2, 1.5 μg) and non-reduced (Lane 2, 1.5 μg) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result, different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

Figure 2 Anti-IAV HA Recombinant Antibody (TAB-027ML) in SEC-HPLC

The purity of TAB-027ML was 97.661% as determined by SEC-HPLC.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl

Figure 3 Anti-IAV HA Recombinant Antibody (TAB-027ML) in ELISA

ELISA analysis of TAB-027ML was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with TAB-027ML. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 4 Anti-IAV HA Recombinant Antibody (TAB-027ML) in ELISA

ELISA analysis of TAB-027ML was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with TAB-027ML. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 5 Anti-IAV HA Recombinant Antibody (TAB-027ML) in ELISA

ELISA analysis of TAB-027ML was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with TAB-027ML. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 6 Anti-IAV HA Recombinant Antibody (TAB-027ML) in ELISA

ELISA analysis of TAB-027ML was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag). Then blocked with BSA and incubated with TAB-027ML. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 7 Anti-IAV HA Recombinant Antibody (TAB-027ML) in WB

Western blot analysis of TAB-027ML was performed with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-027ML and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)

Figure 8 Anti-IAV HA Recombinant Antibody (TAB-027ML) in WB

Western blot analysis of TAB-027ML was performed with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-027ML and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)

Figure 9 Anti-IAV HA Recombinant Antibody (TAB-027ML) in WB

Western blot analysis of TAB-027ML was performed with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-027ML and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)

Figure 10 Anti-IAV HA Recombinant Antibody (TAB-027ML) in DB

Dot Blot analysis of TAB-027ML was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag).

TAB-027ML incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)

Figure 11 Anti-IAV HA Recombinant Antibody (TAB-027ML) in DB

Dot Blot analysis of TAB-027ML was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag).

TAB-027ML incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)

Figure 12 Anti-IAV HA Recombinant Antibody (TAB-027ML) in DB

Dot Blot analysis of TAB-027ML was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag).

TAB-027ML incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)

Figure 13 Anti-IAV HA Recombinant Antibody (TAB-027ML) in DB

Dot Blot analysis of TAB-027ML was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His tag).

TAB-027ML incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)